Immunogenicity Of An Inactivated Hepatitis A Vaccine In Alaska Native Children And Native And Non-Native Adults

The response to an inactivated hepatitis A vaccine was assessed in 307 persons: 163 Alaska Native children, ages 3–6 years, and 144 Native (84) and non-Native (60) adults. All adults received the same vaccine schedule (0, 1, and 12 months), whereas children were randomized to receive three different...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of infectious diseases 1995-03, Vol.171 (3), p.676-679
Main Authors: Mcmahon, Brian J., Williams, James, Bulkow, Lisa, Snowball, Mary, Wainwright, Robert, Kennedy, Margaret, Krause, David
Format: Article
Language:English
Subjects:
Adolescent
Adult
Adults
Age
Age Factors
Alaska
Alaska Natives
Antibodies
Biological and medical sciences
Child, Preschool
Children
Concise Communications
Dosage
Hepatitis A
Hepatitis A Antibodies
Hepatitis A Vaccines
Hepatitis A virus
Hepatitis Antibodies - blood
Hepatovirus - immunology
Human viral diseases
Humans
Indians, North American
Infectious diseases
Medical sciences
Sex Factors
Vaccination
Vaccines, Inactivated - immunology
Viral diseases
Viral hepatitis
Viral Hepatitis Vaccines - administration & dosage
Viral Hepatitis Vaccines - immunology
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The response to an inactivated hepatitis A vaccine was assessed in 307 persons: 163 Alaska Native children, ages 3–6 years, and 144 Native (84) and non-Native (60) adults. All adults received the same vaccine schedule (0, 1, and 12 months), whereas children were randomized to receive three different schedules (0, 1, and 6; 0, 1, and 2; or 0, 1, and 12 months). After one dose, 141 (96%) of 147 children and 129 (90%) of 143 adults responded with levels of antibody to hepatitis A virus > 20 mIU/mL. After three doses, all participants responded. The geometric mean titer (GMT) 1 month after the third dose was significantly higher in children who received the third dose 12 months after the first dose rather than 2 months after the first dose. While there were differences in the GMT of some blood samples by age, sex, and ethnicity, all participants responded to the vaccine.
ISSN:0022-1899
1537-6613
DOI:10.1093/infdis/171.3.676